BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36555159)

  • 1. Modified mRNA Therapeutics for Heart Diseases.
    Magadum A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified mRNA as a Therapeutic Tool for the Heart.
    Kaur K; Zangi L
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):871-880. PubMed ID: 32822006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified mRNA as a Treatment for Myocardial Infarction.
    Wang Y; Wu M; Guo H
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Application of Modified mRNA in Cardiac Regeneration.
    Wang AYL; Chang YC; Chen KH; Loh CYY
    Cell Transplant; 2024; 33():9636897241248956. PubMed ID: 38715279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction.
    Huang CL; Leblond AL; Turner EC; Kumar AH; Martin K; Whelan D; O'Sullivan DM; Caplice NM
    Mol Pharm; 2015 Mar; 12(3):991-6. PubMed ID: 25588055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of Modified mRNA in a Myocardial Infarction Mouse Model.
    Kaur K; Sultana N; Hadas Y; Magadum A; Sharkar MTK; Chepurko E; Zangi L
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Synthesis of Modified mRNA.
    Yoo J; Zangi L
    Methods Mol Biol; 2022; 2573():77-87. PubMed ID: 36040588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified mRNA-Mediated
    Song MH; Yoo J; Kwon DA; Chepurko E; Cho S; Fargnoli A; Hajjar RJ; Park WJ; Zangi L; Jeong D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct reprogramming induces vascular regeneration post muscle ischemic injury.
    Kaur K; Hadas Y; Kurian AA; Żak MM; Yoo J; Mahmood A; Girard H; Komargodski R; Io T; Santini MP; Sultana N; Sharkar MTK; Magadum A; Fargnoli A; Yoon S; Chepurko E; Chepurko V; Eliyahu E; Pinto D; Lebeche D; Kovacic JC; Hajjar RJ; Rafii S; Zangi L
    Mol Ther; 2021 Oct; 29(10):3042-3058. PubMed ID: 34332145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Synthesis of Modified RNA for Cardiac Gene Therapy.
    Sultana N; Sharkar MTK; Hadas Y; Chepurko E; Zangi L
    Methods Mol Biol; 2021; 2158():281-294. PubMed ID: 32857381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Cardiac Delivery of Modified mRNA.
    Sultana N; Magadum A; Hadas Y; Kondrat J; Singh N; Youssef E; Calderon D; Chepurko E; Dubois N; Hajjar RJ; Zangi L
    Mol Ther; 2017 Jun; 25(6):1306-1315. PubMed ID: 28389322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA-Based Protein Replacement Therapy for the Heart.
    Magadum A; Kaur K; Zangi L
    Mol Ther; 2019 Apr; 27(4):785-793. PubMed ID: 30611663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration.
    Labonia MCI; Estapé Senti M; van der Kraak PH; Brans MAD; Dokter I; Streef TJ; Smits AM; Deshantri AK; de Jager SCA; Schiffelers RM; Sluijter JPG; Vader P
    J Control Release; 2024 May; 369():734-745. PubMed ID: 38604385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction.
    Hadas Y; Vincek AS; Youssef E; Żak MM; Chepurko E; Sultana N; Sharkar MTK; Guo N; Komargodski R; Kurian AA; Kaur K; Magadum A; Fargnoli A; Katz MG; Hossain N; Kenigsberg E; Dubois NC; Schadt E; Hajjar R; Eliyahu E; Zangi L
    Circulation; 2020 Mar; 141(11):916-930. PubMed ID: 31992066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.
    Hadas Y; Katz MG; Bridges CR; Zangi L
    Wiley Interdiscip Rev Syst Biol Med; 2017 Jan; 9(1):. PubMed ID: 27911047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of Modified mRNA for Myocardial Delivery.
    Kondrat J; Sultana N; Zangi L
    Methods Mol Biol; 2017; 1521():127-138. PubMed ID: 27910045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.
    Chien KR; Zangi L; Lui KO
    Cold Spring Harb Perspect Med; 2014 Oct; 5(1):a014035. PubMed ID: 25301935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration.
    Kishore R; Magadum A
    J Cardiovasc Dev Dis; 2024 Jan; 11(2):. PubMed ID: 38392252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of Strategy for Modified mRNA Inducing Cardiac-Specific Expression in Mice.
    Huang C; Jia J; Jin K; Zou Y; Tan S; Lu J; Zhu Y; Lin J; Dai Y; Gong H
    J Cardiovasc Transl Res; 2023 Oct; 16(5):1078-1084. PubMed ID: 37155138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model.
    Chen J; Ma Q; King JS; Sun Y; Xu B; Zhang X; Zohrabian S; Guo H; Cai W; Li G; Bruno I; Cooke JP; Wang C; Kontaridis M; Wang DZ; Luo H; Pu WT; Lin Z
    Life Sci Alliance; 2020 Jan; 3(1):. PubMed ID: 31843959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.